p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis

Key Differences from Retatrutide The fundamental differences between GLP-1 receptor peptides and Retatrutide highlight the evolution from single-receptor to multi-receptor therapeutic strategies
For example, quinone-based redox cycling facilitates electron transport within the mitochondria via ubiquinone (Coenzyme Q), and is therefore essential to cellular bioenergetics 4
The 2026-2031 period is likely to witness blended distribution where digital direct-to-consumer solutions coexist with specialty hubs for complex titration and monitoring, diversifying revenue streams within the GLP-1 diabetes drugs market
Importantly, these results do not establish safety in humans
Real examples and ranges to expect Wegovy (semaglutide) cash pricing has been listed by pharmacies and price-data sites in the $1,200 to $1,400 per month range for the branded product, though promotional pricing may offer lower starter-month rates